<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ulster Med J</journal-id><journal-id journal-id-type="pmc">ulstermedj</journal-id><journal-title>The Ulster Medical Journal</journal-title><issn pub-type="ppub">0041-6193</issn><publisher><publisher-name>Ulster Medical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">2278115</article-id><article-id pub-id-type="pmc">2448319</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Medical treatment of impotence with papaverine and phentolamine intracavernosal injection.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dinsmore</surname><given-names>W. W.</given-names></name></contrib></contrib-group><aff>Department of Genitourinary Medicine, Royal Victoria Hospital, Belfast.</aff><pub-date pub-type="ppub"><month>10</month><year>1990</year></pub-date><volume>59</volume><issue>2</issue><fpage>174</fpage><lpage>176</lpage><abstract><p>Intracavernosal injection of papaverine and phentolamine was used in 20 patients with impotence. After six months 14 patients were still using the self-injection treatment. Two patients failed to respond and two patients developed priapism which responded to venesection and metaraminol injection.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="ulstermedj00079-0077.tif" xlink:title="scanned-page" xlink:role="174" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="ulstermedj00079-0078.tif" xlink:title="scanned-page" xlink:role="175" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="ulstermedj00079-0079.tif" xlink:title="scanned-page" xlink:role="176" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

